日本語 
FUJIFILM Cellular Dynamics, Inc. has opened a new headquarters and iPSC manufacturing location in Madison, expanding its reach in regenerative medicine and cell therapy manufacturing, a bit more than before. The site, is connected to Fujifilm’s previously announced $200 million investment, aimed at ramping up research product development and manufacturing capacity across the U.S., more or less.
The new 175,000-square-foot facility is expected to boost production capacity for the company’s iPSC-based products and services by four times. It also brings in new process development labs, cell culture manufacturing labs, and a gene editing center, so it can back future cell therapy programs as well as commercial scale production.
Also Read: Japanese Alzheimer’s Startup Sound Wave Raises $17 Million to Advance Ultrasound-Based Therapy
One big emphasis is the broadening of the company’s iPSC-derived iCell product line which is now being used even more widely for drug discovery and preclinical tests. Demand keeps climbing and, as regulators in the U.S. and Europe keep pressing for alternatives to animal testing, it seems faster than before. Human cell based models are increasingly viewed as more accurate for tracking biological reactions during early drug development, and for those safety evaluation processes across the globe.
English